NCT00543868CompletedPhase 2
MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 462
Study Overview
Brief Summary
This study will determine how if MK0782 is safe and tolerable and to determine how often and the severity of stomach and small intestine ulcers develop following administration of MK0782 plus enteric coated aspirin, rofecoxib 25mg plus enteric coated aspirin, naproxen 500 mg puls enteric coated asprin vs placebo.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy male or non pregnant female
- •18 years of age or older (age at consent)
- •Able to abstain from alcohol, tobacco, spicy foods, limit coffee
- •Able to avoid strenuous activity
- •Able to read and fill out a study diary
Exclusion Criteria
- •You have participated in an investigational drug study within 4 weeks of entering this study
- •Your weight is not within a specific range for the study
- •You have a history of GI problems like a gastric ulcer
- •You have had gastric or intestinal surgery
- •You have had abdominal or chest surgery
- •You are currently abusing drugs or alcohol or have a history of abuse
- •You have a history of psychiatric disorders
- •You are a smoker or have smoked during the last year
Investigators
Similar Trials
Completed
Phase 1
Safety and Tolerability of MK0773 in Healthy Older Men (0773-004)HealthyNCT01017458Merck Sharp & Dohme LLC68
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)PharmacokineticsCancerNCT03326986Merck Sharp & Dohme LLC24
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese VolunteersObesityNCT05900531Kallyope Inc.60
Completed
Phase 1
A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)OsteoporosisNCT00770159Merck Sharp & Dohme LLC78
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 DiabetesType 2 Diabetes Mellitus (T2DM)ObesityNCT06305351Kallyope Inc.25